Identifying biomarkers for knee osteoarthritis severity and progression

IDENTIFICATION OF BIOMARKERS ASSOCIATED WITH THE SEVERITY AND RADIO-CLINICAL PROGRESSION OF KNEE OSTEOARTHRITIS: OBSERVATIONAL STUDY AND BIOLOGICAL COLLECTION FROM JOINT ARTHROCENTESIS TO JOINT PLACEMENT

This study is trying to find specific markers in blood and joint fluid that can help understand how severe knee osteoarthritis is and how it gets worse over time, so we can better manage the condition.

Quick facts

• Study type: Observational
• Enrollment: 300 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Assistance Publique - Hôpitaux de Paris (other)
• Locations: 1 site (Créteil)
• Trial ID: NCT06600958 on ClinicalTrials.gov

What this trial studies

This observational study aims to identify biomarkers in serum, platelet-rich plasma, and synovial fluid that correlate with the severity and clinical progression of knee osteoarthritis (OA). The study will involve patients with unilateral or bilateral symptomatic knee OA, confirmed by X-ray, and will collect biological samples at the time of inclusion and during follow-up. The goal is to establish a biobank that can help predict clinical outcomes and responses to various intra-articular treatments. By understanding these biomarkers, the study seeks to enhance the management of knee OA.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older with symptomatic knee osteoarthritis confirmed by radiological assessment.

Not a fit: Patients with knee osteoarthritis who do not meet the inclusion criteria or have contraindications for participation may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved predictive tools for managing knee osteoarthritis and tailoring treatments to individual patients.

How similar studies have performed: While there have been previous cohorts established for knee osteoarthritis, this study's approach to creating a biobank for biomarkers is relatively novel and has not been extensively tested.

Eligibility criteria

Inclusion Criteria:

* \- Male or female
* Age ≥ 18 years
* Information and consent of the patient or of a third person in case of physical incapacity to sign the consent form
* Unilateral or bilateral symptomatic knee OA (both knees may be included at the same time or at different times) regardless of the level of pain, confirmed radiologically by X-ray dating less than one year \[(Kellgren and Lawrence score ≥2 in at least one of the 3 compartments (medial, lateral or patellofemoral)\] or arthritis of the knee related to a spondyloarthritis or rheumatoid arthritis
* Registered at the social security system

Exclusion Criteria:

* Male or female
* Age ≥ 18 years
* Information and consent of the patient or of a third person in case of physical incapacity to sign the consent form
* Unilateral or bilateral symptomatic knee OA (both knees may be included at the same time or at different times) regardless of the level of pain, confirmed radiologically by X-ray dating less than one year \[(Kellgren and Lawrence score ≥2 in at least one of the 3 compartments (medial, lateral or patellofemoral)\] or arthritis of the knee related to a spondyloarthritis or rheumatoid arthritis
* Registered at the social security system

Where this trial is running

Créteil

• Henri Mondor — Créteil, France (RECRUITING)

Study contacts

• Principal investigator: Florent EYMARD, MD, PhD — Assistance Publique - Hôpitaux de Paris
• Study coordinator: Florent EYMARD, MD, PhD

Conditions: Knee Osteoarthritis, Chronic Inflammatory Rheumatism, Observational study, Knee osteoarthritis, Inflammatory rheumatism, Intra-articular injection, Platelet rich plasma, Hyaluronic acid